1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma

S-E. Al-Batran, Georg-Martin Haag, Thomas J. Ettrich, K Borchert, A. Kretzschmar, Christian Teschendorf, Gabriele Margareta Siegler, M Ebert, Eray Goekkurt, Manfred Welslau, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf O. Bechstein, Peter Reichardt, Timo Gaiser, Disorn Sookthai, Claudia Pauligk, Thorsten Oliver Goetze, Ralf‐Dieter Hofheinz